options, page-16

Hi Pman,
Glyn and Hammond will certainly be in constant contact with partners, particularly the ones with whom we do share lab space by now.


Wether OBJ has enough knowledge to anticipate news 3 months ahead and plan option extensions accordingly, Im not qualified to answer, I doubt anybody is at this point in time.
As we approach the end of the 3 months period to issue new options, you most certainly can argue along your line of thought.
As to say that nothing will eventuate in the short term, it is impossible to say when GSK will update further, we did not hear for a year from our orginal FMCG, as you rightly mention the consumer acceptance testing results are very overdue ( we do not know at this point in time wether GSK is conducting pharmaceutical application tests with our technology or the original FMCG ).
The Strategic Alliance with the new FMCG can become official at any point in time, there is really no time limit attached as it is impossible to say when first evaluations are met so that the Alliance can be announced and further pipeline evaluation be conducted.

We also can hear at any point in time news about industrial applications which as so far not have yet produced concrete announcements.


The most important issue with OBJ though is that the announcement calendar is near impossible to anticipate and I, for my my part, have been repeatedly surprised by who announced and at what time.